Press release BoxID: 122821 (ProBioGen AG)
  • ProBioGen AG
  • Goethestr. 54
  • 13086 Berlin
  • Contact person
  • Michael Schlenk
  • +49 (30) 924006-0

ProBioGen reinforces its Business Development Team

(PresseBox) (Berlin, ) ProBioGen AG today announces that Dr Klaus Stünkel will take over the position of Vice President Business Development Licensing with immediate effect. Mr Stünkel brings with him experience gathered over many years in the areas of Business Development (including 15 years in licensing) and R&D at Bayer AG. Herewith a broad international network and profound knowledge of licensing business will become accessible to ProBioGen.

From 1 July 2007 Dr Gabriele Schneider took over the position of Vice President Business Development Services. Having worked in Business Development of ProBioGen since late 2003 Ms Schneider has been instrumental in the economic success of the company in recent years.

From 1 August 2007 Dr Peter-Paul Henze took up his position as Director Contract Manufacturing Services. Mr Henze can draw on 16 years of sales and marketing experience with various Life Science companies.
Dr Hing Kin Chan will leave ProBioGen with immediate effect in order to concentrate on other challenges.

“A further reinforcement und additional specialization of the team was necessary in order to live up to the requirements of the strongly growing ProBioGen”, Michael Schlenk, CEO remarks. „The company has had an average annual growth of ca. 50% since 2002. This streak of success that has put us among the few profitable Biotechnology companies in Europe needs to be consistently pursued further. With Ms Schneider, Mr Stünkel and Mr Henze we are proud of having three proven Business Development professionals by our side.“

ProBioGen AG

ProBioGen is a cell specialist. By combining deep molecular understanding of cells with state-of-the-art industry process engineering and production know-how, ProBioGen's technologies enable biopharmaceutical companies to develop products with superior efficiency, safety and a more favourable cost profile. Since its inception in 1994, the company has processed more than 300 cell lines and established a GMP unit based on disposable reactor technology, which supports all currently available manufacturing processes. The company is headquartered in Berlin.

For more information, please visit